JPRN-UMIN000006686已完成未知
Therapeutic Effect of Irbesartan, AVAPRO, on Blood Pressure and eGFR by Morning or Bedtime Administration in Chronic Kidney Disease Patients(ABPM-CKD) - ABPM-CKD study
Department of Nephrology, Nagoya university graduate school of medicine0 个研究点目标入组 30 人开始时间: 2011年11月8日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Pregant or possible pregnant patients 2)Patients with bilareral renal artery stenosis and patients with unilateral and renal artery stenosis 3)Nephrotic syndrome 4)Patients whose hepatic function was over 2 times higher than normal upper limit within eight weekss before the informed consent acquisition 5)Patients received hospitalizing by onset of cardiovascular disease, myocardial infarction, cerebral apoplexy, cardiac insufficiency within eight weeks before the informed consent acquisition 6)Allergic reaction to irbesartan 7)Judged inappropriate for this study by the physicians
研究者
相似试验
已完成
4 期
Effects of the combination therapy of irbesartan and indapamide in chronik kidney disease with hypertensiochronick kidney disease with hypertensionJPRN-UMIN000010787Division of Nephrology, Department of Internal medicine, Jichi Medical University30
进行中（未招募）
不适用
PROJECT TITLE: EFFECTS OF ATORVASTATIN ON BLOOD PRESSURE AND URINARY ALBUMIN EXCRETION IN PATIENTS WITH ESSENTIAL HYPERTENSION - ST.A.Y50 patients with hypertension and newly diagnosed mild hypercholesterolemia.MedDRA version: 8.1Classification code 10062060EUCTR2006-001669-41-GRThessaloniki's Aristoteleio University50
招募中
不适用
Effect of on combination therapy with irbesartan and amlodipine besilate on clinical blood pressure, home blood pressure and blood pressure variability in hypertensive patients with chronic kidney diseaseHypertension with chronic kidney disease (CKD G1-G4)JPRN-UMIN000013213Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine30
进行中（未招募）
1 期
Irbesartan in the treatment of Hypertensive Patients with Metabolic Syndrome.Irbesartan en el tratamiento del paciente hipertenso con síndrome metabólicoHypertension, nosEUCTR2005-000614-12-ESBristol Myers Squibb International Corporation540
进行中（未招募）
不适用
Irbesartan in the treatment of Hypertensive Patients with Metabolic Syndrome.Revised Protocol 2, incorporating Protocol Amendments 01 dated 09-Jan-06 & 02 dated 05-Oct-2006. And Protocol amendment 03 dated 24-Oct-2006 - Biomarkers Substudy.EUCTR2005-000614-12-DEBristol Myers Squibb International Corporation540